Barry Ticho Sells 1,461 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

Key Points

• Insider sale: Director Barry Ticho sold 1,461 shares on March 19 at $29.99 (≈$43,815) and also sold 6,686 and 6,164 shares on March 18 and 17, respectively, for cumulative proceeds of roughly $456,800, reducing his stake to 40,702 shares (~$1.22M).
• Stock action: STOK traded up to $33.19 on above-average volume (853,428 vs. avg 754,489), with a market cap of about $1.96 billion and a 52‑week range of $5.35–$40.22.
• Analyst/earnings split: Multiple analysts raised price targets and the consensus rating is a “Moderate Buy” (consensus PT $39.83), but the company recently missed quarterly EPS and revenue estimates, which is a near-term negative catalyst.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) insider Barry Ticho sold 1,461 shares of Stoke Therapeutics stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $29.99, for a total transaction of $43,815.39. Following the sale, the insider owned 40,702 shares of the company's stock, valued at approximately $1,220,652.98. The trade was a 3.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Barry Ticho also recently made the following trade(s):

• On Wednesday, March 18th, Barry Ticho sold 6,686 shares of Stoke Therapeutics stock. The shares were sold at an average price of $31.34, for a total transaction of $209,539.24.
• On Tuesday, March 17th, Barry Ticho sold 6,164 shares of Stoke Therapeutics stock. The stock was sold at an average price of $33.01, for a total transaction of $203,473.64.

Stoke Therapeutics Stock Performance

Shares of Stoke Therapeutics stock traded up $2.17 during trading on Thursday, hitting $33.19. 853,428 shares of the company's stock were exchanged, compared to its average volume of 754,489. The stock has a market capitalization of $1.96 billion, a price-to-earnings ratio of 49.54 and a beta of 1.07. The business has a 50-day simple moving average of $32.61 and a 200-day simple moving average of $29.90. Stoke Therapeutics, Inc. has a 52-week low of $5.35 and a 52-week high of $40.22.

Analyst Ratings Changes

Several analysts recently commented on the stock. Needham & Company LLC raised their price target on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the company a "buy" rating in a research report on Tuesday. Wedbush increased their target price on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the stock an "outperform" rating in a research note on Tuesday. HC Wainwright lifted their price target on Stoke Therapeutics from $35.00 to $50.00 and gave the company a "buy" rating in a research note on Monday, December 15th. Canaccord Genuity Group upped their price target on Stoke Therapeutics from $28.00 to $36.00 and gave the stock a "buy" rating in a report on Monday, January 5th. Finally, Guggenheim assumed coverage on Stoke Therapeutics in a report on Thursday, February 5th. They issued a "buy" rating and a $60.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $39.83.

Stoke Therapeutics News Roundup

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Multiple analysts raised or reiterated bullish ratings and price targets this week (BTIG reaffirmed "buy" with a $39 target; Wedbush lifted its target to $38; Needham raised its target toward $40 and Chardan keeps a $35 target) — these actions increase buy-side interest and provide technical/supportive buying. Read More.
• Positive Sentiment: Pipeline story: coverage highlighting STK‑001’s potential to restore developmental deficits in Dravet syndrome (beyond seizure control) supports upside for long-term clinical value if trials continue to show benefit. Read More.
• Neutral Sentiment: Company granted inducement stock options to new hires — helps recruiting but adds potential future dilution; not an immediate earnings impact. Read More.
• Negative Sentiment: Quarterly results missed expectations: EPS of ($0.97) vs. consensus ($0.75) and revenue $1.4M vs. $5.3M expected — the earnings/revenue shortfall is the clearest near-term driver of prior downward pressure and investor concern about near-term commercialization/visibility. Read More.
• Negative Sentiment: Insider sale disclosed — Director Arthur A. Levin sold 605 shares (~$22k) in mid‑March; small in dollar terms but sometimes interpreted as a mild negative signal by short‑term traders. Read More.

Institutional Trading of Stoke Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Stoke Therapeutics by 5.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company's stock valued at $162,000 after buying an additional 1,149 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in Stoke Therapeutics by 21.4% during the first quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company's stock worth $11,053,000 after acquiring an additional 293,072 shares during the last quarter. Jane Street Group LLC boosted its position in Stoke Therapeutics by 125.2% during the first quarter. Jane Street Group LLC now owns 26,978 shares of the company's stock worth $179,000 after acquiring an additional 15,001 shares during the last quarter. Geode Capital Management LLC grew its stake in Stoke Therapeutics by 7.9% during the 2nd quarter. Geode Capital Management LLC now owns 972,921 shares of the company's stock valued at $11,044,000 after acquiring an additional 70,935 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey grew its stake in Stoke Therapeutics by 33.2% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,558 shares of the company's stock valued at $108,000 after acquiring an additional 2,384 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.